Michael Goldbrunner
Impact in
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 2
- Cancer therapeutics and mechanisms 1
-
- Lung Cancer Treatments and Mutations 2
- Blood properties and coagulation 1
- Co-authors
- Erwin von Angerer (2 shared papers)Howard A. Burris (3 shared papers)Qinhua Ru (2 shared papers)José Baselga (2 shared papers)Jordi Rodón (2 shared papers)Stefan S. De Buck (2 shared papers)David Demanse (2 shared papers)Diana C. Birle (2 shared papers)
- Journals
- Journal of Clinical Oncology (3 papers)Journal of Medicinal Chemistry (2 papers)Blood Advances (1 paper)Investigational New Drugs (1 paper)European Journal of Cancer Supplements (1 paper)
- Partner nations
- GermanySwitzerlandHong Kong
In The Last Decade
Michael Goldbrunner
9 papers receiving 936 citations
Michael Goldbrunner's Hit Papers
Peers
Comparison fields: 5 of 65
- Genetics 113
- Oncology 227
- Cancer Research 114
- Organic Chemistry 241
- Molecular Biology 523
Countries citing papers authored by Michael Goldbrunner
This map shows the geographic impact of Michael Goldbrunner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Goldbrunner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Goldbrunner more than expected).
Fields of papers citing papers by Michael Goldbrunner
This network shows the impact of papers produced by Michael Goldbrunner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Goldbrunner. The network helps show where Michael Goldbrunner may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Goldbrunner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors Hit paper breakdown → | 2011 | 558 |
| 2 | 1997 | 133 | |
| 3 | 1998 | 109 | |
| 4 | 2005 | 50 | |
| 5 | 2010 | 42 | |
| 6 | 2013 | 39 | |
| 7 | 2008 | 19 | |
| 8 | 2022 | 5 | |
| 9 | 2003 | 1 |
About Michael Goldbrunner
Michael Goldbrunner is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Organic Chemistry and Genetics, having authored 9 papers that have together received 956 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Blood properties and coagulation (1 paper), Synthesis and Reactivity of Heterocycles (1 paper), Bioactive Compounds and Antitumor Agents (1 paper), Synthesis and pharmacology of benzodiazepine derivatives (1 paper), Blood groups and transfusion (1 paper) and Cancer therapeutics and mechanisms (1 paper). The work is most often cited by research in Genetics (113 citations), Oncology (227 citations), Cancer Research (114 citations), Organic Chemistry (241 citations) and Molecular Biology (523 citations). Michael Goldbrunner has collaborated with scholars based in Germany, Switzerland and Hong Kong. Frequent co-authors include Erwin von Angerer, Howard A. Burris, Qinhua Ru, José Baselga, Jordi Rodón, Stefan S. De Buck, David Demanse, Diana C. Birle, Malte Peters and Johanna C. Bendell. Their work appears in journals such as Journal of Clinical Oncology, Journal of Medicinal Chemistry, Blood Advances, Investigational New Drugs and European Journal of Cancer Supplements.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.